Virus-like particle (VLP)-based vaccines for pandemic influenza: Performance of a VLP vaccine during the 2009 influenza pandemic

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 3, 2012, Pages 402-405

  López Macías, Constantino ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Clinical trials; H1N1; Influenza; Pandemic; Vaccination; Vaccines; Virus like particles

Indexed keywords

EPITOPE; INFLUENZA VACCINE; PLACEBO; RECOMBINANT PROTEIN; VIRUS LIKE PARTICLE VACCINE;

ANTIBODY TITER; BACULOVIRUS; DRUG EFFICACY; DRUG SAFETY; EGG; EPIDEMIC; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INNATE IMMUNITY; INSECT CELL; NONHUMAN; NOTE; PANDEMIC INFLUENZA; PLANT CELL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; VACCINE PRODUCTION; VIRUS INFECTION; VIRUS LIKE AGENT; ANIMAL; BIOTECHNOLOGY; GENETICS; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; METHODOLOGY; PANDEMIC; PHARMACEUTICS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SF9 CELL; TOBACCO; TRANSGENIC PLANT;

ANIMALS; BACULOVIRIDAE; BIOTECHNOLOGY; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; PLANTS, GENETICALLY MODIFIED; SF9 CELLS; TECHNOLOGY, PHARMACEUTICAL; TOBACCO; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84874423017     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.3.18757     Document Type: Note

References (30)

1. Fedson DS. Vaccine development for an imminent pandemic: why we should worry, what we must do. Hum Vaccin 2006; 2:38-42; PMID:17012898; http://dx.doi.org/10.4161/hv.2.1.2554
2. European 2009 influenza pandemic timeline, 2010. (http://ecdc.europa.eu/ en/healthtopics/H1N1/Documents/110810_2009_pandemic_European_Timeline.pdf).
3. Chowell G, Echevarría-Zuno S, Viboud C, Simonsen L, Tamerius J, Miller MA, et al. Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico. PLoS Med 2011; 8:e1000436; PMID:21629683; http://dx.doi.org/10.1371/journal.pmed.1000436
4. Charu V, Chowell G, PalacioMejia LS, Echevarría-Zuno S, Borja-Aburto VH, Simonsen L, et al. Mortality burden of the A/H1N1 pandemic in Mexico: a comparison of deaths and years of life lost to seasonal influenza. Clin Infect Dis 2011; 53:985-93; PMID:21976464; http://dx.doi.org/10.1093/cid/ cir644
5. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 2010; 28:4895-902; PMID:20553769; http://dx.doi.org/10.1016/j.vaccine.2010.05.031
6. Vidal P, Reyna J, Saldaña P, Richardson VL. Events temporarily associated with anti-influenza A (H1N1) vaccination in Mexico. Arch Med Res 2011; 42:627-32; PMID:22036935; http://dx.doi.org/10.1016/j.arcmed.2011.10.007
7. Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JP. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS One 2011; 6:e24384; PMID:21915319; http://dx.doi.org/10.1371/journal.pone.0024384
8. Osterholm MTKN, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44; PMID:22032844; http://dx.doi.org/10.1016/ S1473-3099(11)70295-X
9. Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res 2009; 143:140-6; PMID:19374929; http://dx.doi.org/10.1016/j.virusres.2009.04.005
10. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010:174-96.
11. Buonaguro L, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, Kamin-Lewis R, et al. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J Virol 2006; 80:9134-43; PMID:16940524; http://dx.doi.org/10.1128/JVI.00050-06
12. Acosta-Ramírez E, Pérez-Flores R, Majeau N, Pastelin-Palacios R, Gil-Cruz C, Ramírez-Saldaña M, et al. Translating innate response into long-lasting antibody response by the intrinsic antigen-adjuvant properties of papaya mosaic virus. Immunology 2008; 124:186-97; PMID:18070030; http://dx.doi.org/10.1111/j.1365-2567.2007.02753.x
13. Sailaja G, Skountzou I, Quan FS, Compans RW, Kang SM. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 2007; 362:331-41; PMID:17276476; http://dx.doi.org/10.1016/j.virol. 2006.12.014
14. Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993; 262:1448-51; PMID:8248784; http://dx.doi.org/10.1126/science. 8248784
15. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10:787-96; PMID:20948547; http://dx.doi.org/10.1038/nri2868
16. Denis J, Acosta-Ramirez E, Zhao Y, Hamelin ME, Koukavica I, Baz M, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008; 26:3395-403; PMID:18511159; http://dx.doi.org/10.1016/j.vaccine.2008.04.052
17. Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009; 8:435-45; PMID:19348559; http://dx.doi.org/10.1586/erv.09.8
18. Cox MM. Progress on baculovirus-derived influenza vaccines. Curr Opin Mol Ther 2008; 10:56-61; PMID:18228182
19. Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007; 25:3871-8; PMID:17337102; http://dx.doi.org/10.1016/j.vaccine.2007.01.106
20. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001; 75:6154-65; PMID:11390617; http://dx.doi.org/10.1128/ JVI.75.13.6154-6165.2001
21. Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008; 3:e1501.
22. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005; 23:5751-9; PMID:16143432; http://dx.doi.org/10.1016/j.vaccine.2005.07.098
23. Pushko P, Tumpey TM, Van Hoeven N, Belser JA, Robinson R, Nathan M, et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 2007; 25:4283-90; PMID:17403562; http://dx.doi.org/10.1016/j.vaccine.2007.02.059
24. Galarza JM, Latham T, Cupo A. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005; 18:365-72; PMID:16035948; http://dx.doi.org/10.1089/vim.2005.18.365
25. Quan FS, Huang C, CompansRW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 2007; 81:3514-24; PMID:17251294; http://dx.doi.org/10.1128/JVI. 02052-06
26. Kang SM, Pushko P, Bright RA, Smith G, Compans RW. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 2009; 333:269-89; PMID:19768411; http://dx.doi.org/10.1007/978-3-540-92165- 3-14
27. Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, et al. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clin Vaccine Immunol 2011; 18:2010-7; PMID:22030367; http://dx.doi.org/10.1128/CVI.05206-11
28. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5:e15559; PMID:21203523; http://dx.doi.org/10.1371/journal.pone.0015559
29. Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 2010; 28:4771-6; PMID:20470801; http://dx.doi.org/10.1016/j.vaccine.2010.04.093
30. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 2011; 29:7826-34; PMID:21816199; http://dx.doi.org/10.1016/j.vaccine.2011.07.099